The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

ARIAD to Present at the 13th Annual BIO CEO & Investor Conference

Monday, February 07, 2011

ARIAD to Present at the 13th Annual BIO CEO & Investor Conference07:35 EST Monday, February 07, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 13th Annual BIO CEO & Investor Conference being held at the Waldorf=Astoria Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company's robust oncology pipeline and progress on its three lead compounds on Monday, February 14, 2011 at 11:00 a.m. (ET). The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for three weeks. About the BIO CEO & Investor Conference The BIO CEO & Investor Conference is a must-attend event for institutional investors, industry analysts, and senior biotechnology executives focused on shaping the future investment landscape of the biotechnology industry. For more information on the conference, visit http://www.bio.org/bioceo. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit www.ariad.com. ARIAD Pharmaceuticals, Inc.Maria E. Cantor, 617-621-2208